Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro/eortc consensus recommendations.
Liver metastases
Oligometastasis
Oligorecurrences
Stereotactic body radiotherapy
Stereotactic radiosurgery
Journal
Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970
Informations de publication
Date de publication:
17 Jul 2024
17 Jul 2024
Historique:
received:
04
03
2024
accepted:
08
07
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
17
7
2024
Statut:
aheadofprint
Résumé
A large pooled analysis of liver oligometastases, classified accordingly to the ESTRO/EORTC recommendations, treated by stereotactic radiotherapy (SBRT) and Radiosurgery (SRS) was carried out. The clinical and dosimetric data of patients who underwent SBRT/SRS for liver metastases were analysed in terms of efficacy and toxicity profile. In particular, the Local Control (LC), the Distant Metastases Free Survival (DMFS), the Disease-Free Survival (DFS), the Overall Survival (OS), and the Next Systemic Therapy Free Survival (NEST-FS) rates were analysed. 113 patients (M/F: 49/64), accounting for a total of 150 hepatic lesions (March 2006-February 2023) in two Italian radiotherapy Institutions were evaluated. Median age was 67 years old (36-92) and 48 (42.5%) patients had at least one comorbidity. The majority of the lesions were induced (30.7%) or repeated oligoprogressive (12.7%) metastases. 98 lesions were treated with more than one daily fraction (mainly 50 Gy in 5 fractions), while 52 were radiosurgery treatments (mainly 32 Gy). The treatment response at 3-4 months was evaluable in 147 lesions: complete response was 32.0%, partial response 17.0%, and stable disease 32.0%. Actuarial LC, DMFS, DFS, OS, and NEST-FS at 1 year were 75.8%, 37.7%, 34.9%, 78.7%, and 59.4% respectively; while actuarial LC, DMFS, DFS, OS, and NEST-FS at 2 years were 52.1%, 24.9%, 21.9%, 51.3%, and 36.8%, respectively. The achievement of complete response, synchronous oligometastases, and no treatment interruptions correlated with a more favorable outcomes. As per the toxicity profile, we registered only two acute and one late toxicity cases higher than grade 2. Stereotactic treatment for liver metastases seems to be a safe and promising option in terms of local control. The best results in term of outcomes have been obtained in patients with complete response, synchronous oligometastases, favorable histology, and no treatment interruptions.
Identifiants
pubmed: 39017807
doi: 10.1007/s10585-024-10301-6
pii: 10.1007/s10585-024-10301-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
de la Peña C, Gonzalez MF, González C, Salazar JM, Cruz B (2020) Stereotactic body radiation therapy for liver metastases: clinical outcomes and literature review. Rep Pract Oncol Radiother 25(4):637–642. https://doi.org/10.1016/j.rpor.2020.04.021
doi: 10.1016/j.rpor.2020.04.021
pubmed: 32565742
pmcid: 7287194
Wulf J, Hadinger U, Oppitz U et al (2001) Stereotactic radiotherapy of targets in thelung and liver. Strahlenther Oncol 177(12):645–655
doi: 10.1007/PL00002379
Wulf J, Guckenberger M, Haedinger U et al (2006) Stereotactic radiotherapy of pri-mary liver cancer and hepatic metastases. Acta Oncol 45:838–847
doi: 10.1080/02841860600904821
pubmed: 16982548
Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P (2007) Hypofractionated stereotactic body radiation therapy (SBRT) for limited hep-atic metastases. Int J Radiat Oncol Biol Phys 67(3):793–798
doi: 10.1016/j.ijrobp.2006.10.025
pubmed: 17197128
Willmann J, Vlaskou Badra E, Adilovic S, Ahmadsei M, Christ SM, van Timmeren JE, Kroeze SGC, Mayinger M, Guckenberger M, Andratschke N (2022) Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: a retrospective single center study. Radiother Oncol 168:256–264. https://doi.org/10.1016/j.radonc.2022.01.019
doi: 10.1016/j.radonc.2022.01.019
pubmed: 35101466
Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10
doi: 10.1200/JCO.1995.13.1.8
pubmed: 7799047
Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R et al (2014) The oligometastatic state—separating truth from wishful thinking. Nat Rev Clin Oncol 11:549–557
doi: 10.1038/nrclinonc.2014.96
pubmed: 24958182
Choti MA, Sitzman JV, Tiburi MF et al (2002) Trends in long-term survivalfollowing liver resection for hepatic colorectal metastases. Ann Surg 235(6):759–766
doi: 10.1097/00000658-200206000-00002
pubmed: 12035031
pmcid: 1422504
Tomlinson JS, Jarnagin WR, DeMatteo RP, Fog Y et al (2007) Actual 10-year sur-vival after resection of colorectal liver metastases defines cure. J Clin Oncol 25(29):4575–4580
doi: 10.1200/JCO.2007.11.0833
pubmed: 17925551
Small R, Lubezky N, Ben-Haim M (2007) Current controversies in the surgicalmanagement of colorectal cancer metastases to the liver. Isr Med Assoc J 9(10):742–747
pubmed: 17987765
Garrean S, Hering J, Saied A, Helton WS, Espat NJ (2008) Radiofrequency ablation ofprimary and metastatic liver tumors: a critical review of the literature. Am J Surg 195(4):508–520
doi: 10.1016/j.amjsurg.2007.06.024
pubmed: 18361927
Solbaiti L, Livraghi T, Golberg SN et al (2001) Percutaneous radiofrequency ablation ofhepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221(1):159–166
doi: 10.1148/radiol.2211001624
Groeschl RT, Pilgrim CH, Hanna EM et al (2014) Microwave ablation for hepatic malig-nancies: a multinstitutional analysis. Ann Surg 259(6):1195–1200
doi: 10.1097/SLA.0000000000000234
pubmed: 24096760
Volg TJ, Zangos S, Eichler K, Yakaoub D, Nabil M (2007) Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hep-atic chemoperfusion: an update. Eur Radiol 17(4):1025–1034
doi: 10.1007/s00330-006-0372-5
Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P, Mancosu P, Reggiori G, Fogliata A, Torzilli G, Tomatis S, Cozzi L (2013) Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 86(2):336–342. https://doi.org/10.1016/j.ijrobp.2012.12.021
doi: 10.1016/j.ijrobp.2012.12.021
pubmed: 23433800
Dawson LA, Normolle D, Balter JM et al (2002) Analysis of radiationinduced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53:810–821
doi: 10.1016/S0360-3016(02)02846-8
pubmed: 12095546
Timmerman RD, Kavanagh BD, Cho LC et al (2007) Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 25:947–952
doi: 10.1200/JCO.2006.09.7469
pubmed: 17350943
Lee J, Shin IS, Yoon WS, Koom WS, Rim CH (2020) Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review. Radiother Oncol 145:63–70. https://doi.org/10.1016/j.radonc.2019.12.004
doi: 10.1016/j.radonc.2019.12.004
pubmed: 31923711
Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P (2020) Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol 21(1):e18–e28. https://doi.org/10.1016/S1470-2045(19)30718-1
doi: 10.1016/S1470-2045(19)30718-1
pubmed: 31908301
Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346
doi: 10.1016/0360-3016(95)00060-C
pubmed: 7713792
National Cancer Institute Common Terminology Criteria for Adverse Events v.4.03 (CTCAEv.4.03)
Schwartz LH, Litière S, de Vries E et al (2016) RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 62:132–137. https://doi.org/10.1016/j.ejca.2016.03.081
doi: 10.1016/j.ejca.2016.03.081
pubmed: 27189322
pmcid: 5737828
Diez P, Hanna GG, Aitken KL, van As N, Carver A, Colaco RJ, Conibear J, Dunne EM, Eaton DJ, Franks KN, Good JS, Harrow S, Hatfield P, Hawkins MA, Jain S, McDonald F, Patel R, Rackley T, Sanghera P, Tree A, Murray L (2022) UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy. Clin Oncol (R Coll Radiol) 34(5):288–300. https://doi.org/10.1016/j.clon.2022.02.010
doi: 10.1016/j.clon.2022.02.010
pubmed: 35272913
van der Pool AE, Méndez Romero A, Wunderink W et al (2010) Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 97(3):377–382. https://doi.org/10.1002/bjs.6895
doi: 10.1002/bjs.6895
pubmed: 20095016
Méndez Romero A, Wunderink W, Hussain SM et al (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i–ii study. Acta Oncol 45(7):831–837. https://doi.org/10.1080/02841860600897934
doi: 10.1080/02841860600897934
pubmed: 16982547
Rusthoven KE, Kavanagh BD, Cardenes H et al (2009) multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27(10):1572–1578. https://doi.org/10.1200/JCO.2008.19.6329
doi: 10.1200/JCO.2008.19.6329
pubmed: 19255321
Jackson WC, Tao Y, Mendiratta-Lala M et al (2018) Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases. Int J Radiat Oncol Biol Phys 100(4):950–958. https://doi.org/10.1016/j.ijrobp.2017.12.014
doi: 10.1016/j.ijrobp.2017.12.014
pubmed: 29485074
Petrelli F, Comito T, Barni S et al (2018) Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review. Radiother Oncol 129(3):427–434. https://doi.org/10.1016/j.radonc.2018.06.035
doi: 10.1016/j.radonc.2018.06.035
pubmed: 29997034
Lanciano R, Lamond J, Yang J et al (2012) Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors. Front Oncol 2:23. https://doi.org/10.3389/fonc.2012.00023
doi: 10.3389/fonc.2012.00023
pubmed: 22645716
pmcid: 3355825
Lee MT, Kim JJ, Dinniwell R et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27(10):1585–1591. https://doi.org/10.1200/JCO.2008.20.0600
doi: 10.1200/JCO.2008.20.0600
pubmed: 19255313
Rule W, Timmerman R, Tong L et al (2011) Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 18(4):1081–1087. https://doi.org/10.1245/s10434-010-1405-5
doi: 10.1245/s10434-010-1405-5
pubmed: 21046264
Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Muacevic A (2010) Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients. Eur J Cancer 46(6):1026–1032. https://doi.org/10.1016/j.ejca.2010.01.008
doi: 10.1016/j.ejca.2010.01.008
pubmed: 20153959
Uder L, Nachbar M, Butzer S, Boldt J, Baumeister S, Bitzer M, Königsrainer A, Seufferlein T, Hoffmann R, Gatidis S, Nikolaou K, Zips D, Thorwarth D, Gani C, Boeke S (2023) Local control and patient reported outcomes after online MR guided stereotactic body radiotherapy of liver metastases. Front Oncol 12:1095633. https://doi.org/10.3389/fonc.2022.1095633
doi: 10.3389/fonc.2022.1095633
pubmed: 36727060
pmcid: 9885175
Ugurluer G, Mustafayev TZ, Gungor G et al (2021) Stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic patients: initial clinical experience. Radiat Oncol J 39(1):33–40. https://doi.org/10.3857/roj.2020.00976
doi: 10.3857/roj.2020.00976
pubmed: 33794572
pmcid: 8024184
Yu J, Kim DH, Lee J et al (2022) Radiofrequency ablation versus stereotactic body radiation therapy in the treatment of colorectal cancer liver metastases. Cancer Res Treat 54(3):850–859. https://doi.org/10.4143/crt.2021.674
doi: 10.4143/crt.2021.674
pubmed: 34645129
Macchia G, Lazzari R, Colombo N et al (2020) A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 Study): a collaboration of MITO, AIRO GYN, and MaNGO groups. Oncologist 25(2):e311–e320
doi: 10.1634/theoncologist.2019-0309
pubmed: 32043791
Macchia G, Nardangeli A, Laliscia C et al (2022) Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups. Int J Gynecol Cancer 32(6):732–739
doi: 10.1136/ijgc-2021-003237
pubmed: 35193941
Macchia G, Pezzulla D, Campitelli M et al (2023) Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic uterine cancer (MITO-RT2/RAD study): a large, real-world study in collaboration with AIRO GYN, MITO and MANGO groups. Int J Radiat Oncol Biol Phys 32(7):1
Cilla S, Campitelli M, Antonietta Gambacorta M, Michela Rinaldi R, Deodato F, Pezzulla D, Romano C, Fodor A, Laliscia C, Trippa F, De Sanctis V, Ippolito E, Ferioli M, Titone F, Russo D, Balcet V, Vicenzi L, Di Cataldo V, Raguso A, Giuseppe Morganti A, Ferrandina G, Macchia G (2023) Machine-learning prediction of treatment response to stereotactic body radiation therapy in oligometastatic gynecological cancer: a multi-institutional study. Radiother Oncol 191:110072. https://doi.org/10.1016/j.radonc.2023.110072
doi: 10.1016/j.radonc.2023.110072
pubmed: 38142932
Klement RJ, Abbasi-Senger N, Adebahr S et al (2019) The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer 19(1):173. https://doi.org/10.1186/s12885-019-5362-5
doi: 10.1186/s12885-019-5362-5
pubmed: 30808323
pmcid: 6390357
Reynders K, Illidge T, Siva S et al (2015) The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 41:503–510
doi: 10.1016/j.ctrv.2015.03.011
pubmed: 25872878
pmcid: 4816218
Joo JH, Park J-H, Kim JC, Chang Sik Y, Lim S-B, Park IJ, Kim TW, Hong YS, Kim K-P, Yoon SM, Park J, Kim JH (2017) Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys 99(4):876–883. https://doi.org/10.1016/j.ijrobp.2017.07.030
doi: 10.1016/j.ijrobp.2017.07.030
pubmed: 29063852
Chang DT, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117(17):4060–4069. https://doi.org/10.1002/cncr.25997
doi: 10.1002/cncr.25997
pubmed: 21432842
Aitken K, Tree A, Thomas K et al (2015) Initial UK experience of stereotactic body radiotherapy for extracranial oligometastases: can we change the therapeutic paradigm? Clin Oncol (R Coll Radiol) 27(7):411–419. https://doi.org/10.1016/j.clon.2015.03.006
doi: 10.1016/j.clon.2015.03.006
pubmed: 25912366
Folkert MR, Meyer JJ, Aguilera TA et al (2021) Long-term results of a phase 1 dose-escalation trial and subsequent institutional experience of single-fraction stereotactic ablative radiation therapy for liver metastases. Int J Radiat Oncol Biol Phys 109(5):1387–1395. https://doi.org/10.1016/j.ijrobp.2020.12.012
doi: 10.1016/j.ijrobp.2020.12.012
pubmed: 33340601
Goodman KA, Wiegner EA, Maturen KE et al (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78(2):486–493. https://doi.org/10.1016/j.ijrobp.2009.08.020
doi: 10.1016/j.ijrobp.2009.08.020
pubmed: 20350791
Hoyer M, Roed H, Traberg Hansen A et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45(7):823–830. https://doi.org/10.1080/02841860600904854Rusthoven
doi: 10.1080/02841860600904854Rusthoven
pubmed: 16982546
Nicosia L, Cuccia F, Mazzola R, Figlia V, Giaj-Levra N, Ricchetti F, Rigo M, Bonù M, Corradini S, Tolia M, Alongi F (2020) Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. J Cancer Res Clin Oncol 146(9):2351–2358. https://doi.org/10.1007/s00432-020-03223-9
doi: 10.1007/s00432-020-03223-9
pubmed: 32356176
Baker S, Mou B, Jiang W, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Berrang T, Bang A, Chng N, Matthews Q, Tyldesley S, Olson RA (2022) Validation of the prognostic utility of ESTRO/EORTC oligometastatic disease classification: a secondary analysis from the population-based phase II SABR-5 trial. Int J Radiat Oncol Biol Phys 114(5):849–855. https://doi.org/10.1016/j.ijrobp.2022.08.026
doi: 10.1016/j.ijrobp.2022.08.026
pubmed: 36302495